Clinical Chemistry Analyzer Market Size, Share, Opportunities, And Trends By Product (Analyzers, Reagents, Others), By Test (Basic Metabolic Panel, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Panel, Specialty Chemical Tests), By End-Use (Hospitals, Academic Research Centers, Diagnostic Laboratories, Others), And By Geography - Forecasts From 2023 To 2028

The clinical chemistry analyzer market is expected to grow at a CAGR of 4.16% to reach a market size of US$16.36 billion by 2028.

A clinical chemistry analyzer or biochemistry analyzer is a medical device used in clinical laboratories to perform various biochemical tests on patient samples, such as blood, urine, or other body fluids. The increasing prevalence of chronic diseases coupled with the growing aging population around the globe is a major growth driver of the clinical chemistry analyzer market. Moreover, the rising need for automation and adoption of precision medicine along with technological advancements and growing screening awareness is further expected to boost the clinical chemistry analyzer market.

Increasing Prevalence of Chronic Diseases

Clinical chemistry analyzers are essential for diagnosing and monitoring these diseases, as they provide crucial information about the patient's biochemical profile and overall health status. The rising incidence of chronic diseases such as diabetes, cardiovascular disorders, kidney diseases, and liver are therefore expected to boost the clinical chemical analyzer market. For instance, an estimated 2 million fatalities were attributed to diabetes and diabetes-related kidney disease in 2019 according to the WHO. Moreover, in the United States, there are more than 100 million people who suffer from liver disease. Adult deaths from liver disease in the U.S. reached 51,642 in 2020 according to American Liver Foundation.

Growing Aging Population

The global population is aging, leading to a higher prevalence of age-related diseases and conditions thereby propelling the clinical chemical analyzer market. Chronic diseases including diabetes, arthritis, and heart disease have a disproportionately negative impact on older persons. Nearly 80% of people have two or more chronic conditions, and nearly 95% have at least one according to the National Council of Aging. Moreover, the percentage of people aged over 60 years worldwide will increase from 12% to 22% between 2015 and 2050 according to the WHO. Additionally, life expectancy has improved from 66.8 years in 2000 to 73.3 years in 2019 as per the WHO report which is also adding to the aging population.

Rising Adoption of Point-of-Care Testing

The ease and speed of point-of-care testing are making it more and more popular. Clinical chemical analyzers designed for POCT settings are in high demand, especially in remote or resource-limited areas. Therefore, the rising adoption of point-of-care testing is contemplated to aid the clinical chemical analyzer market. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), around 95% of healthcare centers in the United States offered telehealth services during the pandemic. Leading companies in the market are actively working on enhancing their bench-top and portable testing solutions to stay competitive and offer more advanced diagnostic options. For instance, Una Health announced in March 2022 that it will collaborate with Siemens Healthineers to increase the patient-side immunoassay analyzer Atellica VTLi's distribution network in the United Kingdom.

Rising Need for Automation

Laboratories face increasing sample volumes, creating a need for automation to streamline processes and reduce human errors. Rising demand for automation is contemplated to aid the clinical chemical analyzer market with automation capabilities.  According to the Johns Hopkins report in July 2023, an estimated 795,000 Americans each year are killed or rendered permanently crippled by diagnostic mistakes across all clinical settings, including hospital and clinic-based treatment. Moreover, the cost of medication errors worldwide is estimated by the WHO to be $42 billion per year. The huge burden of data and samples necessitates the automation which a clinical chemical analyzer can provide.

Growing Awareness and Screening Programs

Increased awareness of preventive healthcare and the implementation of disease-specific screening programs in various regions boost the clinical chemistry analyzer market to support these initiatives. For instance, the cancer screening program in urban China was initiated in 2012 which covered 42 cities in 20 provincial-level administrative regions by 2021. Moreover, Scripps MD Anderson Cancer Center launched a multidisciplinary lung cancer screening program for residents across San Diego County in November 2022. The program aims to significantly fill an unmet demand by increasing the number of low-dose CT scan screenings.

North America is Expected to Grow Significantly

North America is expected to hold a significant share of the clinical chemistry analyzer market during the forecast period. The factors attributed to such a share are the aging population, the higher burden of chronic diseases, technological advancements, the adoption of point-of-care testing, and rising research investments. For instance, according to the National Council on Aging, there are already 56 million older adults in the United States in 2020, which is expected to reach 56 million people by 2060. A 65-year-old may anticipate a further 17 years of life on average. Further, approximately three million individuals aged 65 years and above seek medical attention in emergency departments due to unintentional fall-related injuries every year.

Major Market Players

• Randox specializes in the development, manufacture, and distribution of innovative diagnostic solutions for healthcare professionals, laboratories, and point-of-care testing. RX Series of the company offers routine chemistries, particular proteins, lipids, therapeutic medicines, antioxidants, and veterinary, and diabetic testing in the menu of specific clinical chemistry tests.
• Mindray Medical International Limited is a leading medical technology company based in China. Mindray's product portfolio includes a wide range of medical devices, such as patient monitors, anaesthesia machines, and ultrasound systems. The company launched a BS-600M chemistry analyzer in May 2022 to empower medium-volume laboratories.
• Cardinal Health is a global healthcare services and products company based in the United States. It operates in various segments of the healthcare industry, including pharmaceutical distribution, medical products manufacturing, and healthcare solutions. ASI Evolution®  Ortho VITROS® 4600 Chemistry System and Ortho VITROS 5600 Integrated System are offered by the company.

Key Market Developments

• In July 2023, Siemens Healthineers launched the Atellica CI analyzer to tackle lab challenges that impede productivity. It is designed for immunoassay and clinical chemistry testing which aims to address labor shortage pain points and fosters agility beyond clinical equivalence.
• In February 2023, Erba launched an XL range of four fully automated clinical chemistry systems that incorporate state-of-the-art features. It guarantees high-resolution measurement with an automatic sample conveyor for comfortable workflow in high sample throughput laboratories.
• In September 2021, Roche launched Cobas Pure which is an integrated solutions analyzer offering more than 230 tests across disease areas including infectious diseases, oncology, and cardiology. It reduces plastic generation per result by up to 78% due to the smaller size of the reagent package.

Clinical Chemistry Analyzer Market Scope:

 

Report Metric	Details
Market Size Value in 2028	US$16.36 billion
Growth Rate	CAGR of 4.16% from 2021 to 2028
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Product, Test, End-Use, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Beckanm Coulter, Siemens Healthineers, Roche, Randox, Mindray Global, Agappe, FURUNO, Cardinal Health, Horiba, Fisher Scientific
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Product
  • Analyzers
  • Reagents
  • Others
• By Test
  • Basic Metabolic Panel
  • Electrolyte Panel
  • Liver Panel
  • Lipid Profile
  • Renal Profile
  • Thyroid Function Panel
  • Specialty Chemical Tests
• By End-Use
  • Hospitals
  • Academic Research Centers
  • Diagnostic Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT

5.1. Introduction

5.2. Analyzers

5.3. Reagents

5.4. Others

6. CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST

6.1. Introduction

6.2. Basic Metabolic Panel

6.3. Electrolyte Panel

6.4. Liver Panel

6.5. Lipid Profile

6.6. Renal Profile

6.7. Thyroid Function Panel

6.8. Specialty Chemical Tests

7. CLINICAL CHEMISTRY ANALYZERS MARKET, BY END-USE

7.1. Introduction

7.2. Hospitals

7.3. Academic Research Centers

7.4. Diagnostic Laboratories

7.5. Others

8. CLINICAL CHEMISTRY ANALYZERS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Beckanm Coulter

10.2. Siemens Healthineers

10.3. Roche

10.4. Randox

10.5. Mindray Global

10.6. Agappe

10.7. FURUNO

10.8. Cardinal Health

10.9. Horiba

10.10. Fisher Scientific

Beckanm Coulter

Siemens Healthineers

Roche

Randox

Mindray Global

Agappe

FURUNO

Cardinal Health

Horiba

Fisher Scientific